Eli Lilly (LLY)
(Delayed Data from NYSE)
$918.52 USD
-2.97 (-0.32%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $917.81 -0.71 (-0.08%) 7:58 PM ET
1-Strong Buy of 5 1
F Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Eli Lilly and Company [LLY]
Reports for Purchase
Showing records 61 - 80 ( 439 total )
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Solid Tumors - Week Ended June 2.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Solid Tumors - Week Ended April 7.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for LLY 41123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for LLY 4123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Biotechnology- Weekly Retail Sales Tracker for Solid Tumors - Week Ended March 24.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Solid Tumors - Week Ended March 17.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for LLY 32123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for LLY 31123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for LLY 3123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Solid Tumors - Week Ended February 17.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for LLY 22123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Solid Tumors - Week Ended February 10.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for LLY 21123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for LLY 2123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for LLY 12123
Provider: Stock Traders Daily
Analyst: Research Department